AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25052178 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based VR intervention
Number of subjects: 262
Study 22883656 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital photography as source documentation for skin toxicity assessment
Number of subjects: 552
Study 22883656 — intervention group
Group type: COMPARATOR
Intervention: Clinical scoring of skin reactions
Number of subjects: 552
Study 20513463 — intervention group
Group type: EXPERIMENTAL
Intervention: Recontacted at 1 month
Number of subjects: 605
Study 20513463 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 605
Study 18462105 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin supplementation
Number of subjects: 0
Study 18462105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16943538 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose craniospinal radiotherapy (CSRT) at 23.4 Gy plus adjuvant chemotherapy with lomustine (CCNU), cisplatin, and vincristine
Number of subjects: 379
Study 16943538 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose craniospinal radiotherapy (CSRT) at 23.4 Gy plus adjuvant chemotherapy with cyclophosphamide, cisplatin, and vincristine
Number of subjects: 379
Study 16943538 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as standard treatment)
Number of subjects: 379
Study 16943538 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with areas of frank dissemination
Number of subjects: 379
Study 16943538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide arm
Number of subjects: 379
Study 16943538 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU regimen
Number of subjects: 379
Study 12886872 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan/cisplatin
Number of subjects: 0
Study 10743862 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanon (test)
Number of subjects: 15
Study 10743862 — intervention group
Group type: COMPARATOR
Intervention: Polylactide acetyltributyl citrate (control)
Number of subjects: 15
Study 8959151 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocitrate dehydrogenase (IDH)
Number of subjects: 0
Study 8959151 — intervention group
Group type: EXPERIMENTAL
Intervention: Malate dehydrogenase (MDH)
Number of subjects: 0
Study 8959151 — intervention group
Group type: COMPARATOR
Intervention: Controls (sera from non-tuberculous patients)
Number of subjects: 0
Study 1286488 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine (10 to 40 mg daily for 12 months)
Number of subjects: 45
Study 1286488 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril (15 to 60 mg daily for 12 months)
Number of subjects: 45
Study 2408842 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 450 mg/d
Number of subjects: 20
Study 2408842 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide 600 mg/d
Number of subjects: 20
Study 2408842 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg/d
Number of subjects: 20
Study 2408842 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs
Number of subjects: 20
Study 31365113 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Medical Rehabilitation (EMR)
Number of subjects: 229
Study 31365113 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care rehabilitation
Number of subjects: 229
Study 31365113 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR
Number of subjects: 229
Study 31365113 — intervention group
Group type: COMPARATOR
Intervention: Nontrained therapists
Number of subjects: 229
Study 29873953 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole 2 mg/d
Number of subjects: 393
Study 29873953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study 26854560 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable group (differential fear conditioning)
Number of subjects: 49
Study 26854560 — intervention group
Group type: COMPARATOR
Intervention: Unpredictable group (non-contingent presentation of CS and US)
Number of subjects: 49
Study 26854560 — intervention group
Group type: COMPARATOR
Intervention: Unpredictable group
Number of subjects: 49
Study 26854560 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable group
Number of subjects: 49
Study 26854560 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 24655228 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Telehealth Education and Activation of Mood (I-TEAM)
Number of subjects: 102
Study 24655228 — intervention group
Group type: COMPARATOR
Intervention: Usual care with in-home nursing plus psychoeducation (UC+P)
Number of subjects: 102
Study 22858403 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (100mg)
Number of subjects: 26
Study 22858403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 21134044 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA plus 24‐mg/mL cohesive gel
Number of subjects: 90
Study 21134044 — intervention group
Group type: COMPARATOR
Intervention: onabotulinumtoxinA alone
Number of subjects: 90
Study 21134044 — intervention group
Group type: COMPARATOR
Intervention: 24‐mg/mL cohesive gel alone
Number of subjects: 90
Study 18062869 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan-rich transfer medium (n=130)
Number of subjects: 279
Study 18062869 — intervention group
Group type: COMPARATOR
Intervention: Conventional transfer medium (n=149)
Number of subjects: 279
Study 16056117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case managers' interventions to client-initiated telephone calls
Number of subjects: 45
Study 16056117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case managers' interventions
Number of subjects: 45
Study 12368933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (ACE inhibitor) for three days
Number of subjects: 11
Study 12368933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9539489 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty with assessment of angiographic quality of dilatation
Number of subjects: 0
Study 9539489 — intervention group
Group type: COMPARATOR
Intervention: Quality of dilatation (optimal vs suboptimal)
Number of subjects: 0
Study 7872876 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal Transient Ischemic Attacks (RTIAs)
Number of subjects: 129
Study 7872876 — intervention group
Group type: COMPARATOR
Intervention: Hemispheric Transient Ischemic Attacks (HTIAs)
Number of subjects: 129
Study 2358388 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program (lecture + handout)
Number of subjects: 6
Study 2358388 — intervention group
Group type: EXPERIMENTAL
Intervention: Handout only
Number of subjects: 6
Study 2358388 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6
Study 382750 — intervention group
Group type: EXPERIMENTAL
Intervention: sulpiride (up to 1,800 mg per day)
Number of subjects: 71
Study 382750 — intervention group
Group type: COMPARATOR
Intervention: chlorpromazine (up to 675 mg)
Number of subjects: 71
Study 29508498 — intervention group
Group type: EXPERIMENTAL
Intervention: Locator-retained mandibular overdentures with implants in the premolar areas (PM group)
Number of subjects: 30
Study 29508498 — intervention group
Group type: COMPARATOR
Intervention: Locator-retained mandibular overdentures with implants in the canine regions (CA group)
Number of subjects: 30
Study 28836851 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange maize consumption
Number of subjects: 88
Study 28836851 — intervention group
Group type: COMPARATOR
Intervention: White maize consumption
Number of subjects: 88
Study 26356086 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC)
Number of subjects: 40
Study 26356086 — intervention group
Group type: COMPARATOR
Intervention: Blanket holding (Control)
Number of subjects: 40
Study 23883812 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollen blocker cream applied three times daily for 30 days
Number of subjects: 30
Study 23883812 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied three times daily for 30 days
Number of subjects: 30
Study 21836471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon α‐2b (1.5 μg/kg/wk) plus fixed ribavirin dose (800 mg/d) or weight‐based ribavirin dose (800 to 1400 mg/d) for 24 or 48 weeks
Number of subjects: 4326
Study 19728183 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 43
Study 19728183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 16458458 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact once daily for 4 weeks
Number of subjects: 0
Study 16458458 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 15548461 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamically oriented psychotherapy
Number of subjects: 622
Study 15548461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 622
Study 15548461 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic psychotherapy
Number of subjects: 622
Study 15548461 — intervention group
Group type: COMPARATOR
Intervention: All treatment subgroups
Number of subjects: 622
Study 10665554 — intervention group
Group type: COMPARATOR
Intervention: pyrimethamine-sulphadoxine alone
Number of subjects: 600
Study 10665554 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrimethamine-sulphadoxine plus one dose of artesunate (4mg/kg bodyweight)
Number of subjects: 600
Study 10665554 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrimethamine-sulphadoxine plus three doses of artesunate (4 mg/kg bodyweight daily for 3 days)
Number of subjects: 600
Study 9091006 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogel (1.5 mg of oestradiol/day) for 24 days each month for 6 months
Number of subjects: 254
Study 9091006 — intervention group
Group type: EXPERIMENTAL
Intervention: Estreva (1.5 mg of oestradiol/day) for 24 days each month for 6 months
Number of subjects: 254
Study 8374375 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide regimen 1: usual morning dose in the evening and evening dose before dawn
Number of subjects: 591
Study 8374375 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide regimen 2: usual morning dose in the evening and evening dose before dawn with a reduction of total dose by a quarter
Number of subjects: 591
Study 8374375 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-fasting)
Number of subjects: 591
Study 3712154 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose formula
Number of subjects: 85
Study 3712154 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose formula
Number of subjects: 85
Study 3712154 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycose formula
Number of subjects: 85
Study 3712154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sucrose‐polycose formula
Number of subjects: 85
Study 31786086 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional ultrasound-accelerated catheter-directed thrombolysis (urokinase with a starting bolus of 250,000 IU in 10 mL NaCl followed by 100,000 IU/h for a maximum of 96 h)
Number of subjects: 184
Study 31786086 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (anticoagulant therapy, compression therapy, early ambulation)
Number of subjects: 184
Study 31786086 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional ultrasound-accelerated catheter-directed thrombolysis
Number of subjects: 184
Study 31786086 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 184
Study 30940087 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-mode (mail-only or web-only)
Number of subjects: 0
Study 30940087 — intervention group
Group type: COMPARATOR
Intervention: Mixed-mode (web-mail or mail-web)
Number of subjects: 0
Study 28591675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg)
Number of subjects: 565
Study 28591675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 565
Study 25628283 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal Chevron osteotomy
Number of subjects: 46
Study 25628283 — intervention group
Group type: COMPARATOR
Intervention: Distal Chevron osteotomy
Number of subjects: 46
Study 23876463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (IGC) for almost 24 h after PCI (n = 54; target glucose 80-140 mg/dl)
Number of subjects: 194
Study 23876463 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycemic control (CGC) (n = 52; target glucose 180-200 mg/dl)
Number of subjects: 194
Study 23876463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (IGC)
Number of subjects: 194
Study 21654268 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg/d
Number of subjects: 202
Study 21654268 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 60 mg/d
Number of subjects: 202
Study 21654268 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg/d
Number of subjects: 202
Study 21654268 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 20 mg/d
Number of subjects: 202
Study 21654268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 21654268 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (all doses)
Number of subjects: 202
Study 19261960 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tramadol infiltration
Number of subjects: 60
Study 19261960 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tramadol administration
Number of subjects: 60
Study 16357094 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet (250 mmol/day)
Number of subjects: 24
Study 16357094 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet (70 mmol/day)
Number of subjects: 24
Study 15310527 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily for 24 weeks
Number of subjects: 106
Study 11710656 — intervention group
Group type: EXPERIMENTAL
Intervention: Superslow (SS) strength training
Number of subjects: 14
Study 11710656 — intervention group
Group type: COMPARATOR
Intervention: Traditional Nautilus-style (TR) strength training
Number of subjects: 14
Study 11710656 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SS and TR)
Number of subjects: 14
Study 11710656 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training alone
Number of subjects: 14
Study 9412311 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6, 50 mg/d
Number of subjects: 29
Study 9412311 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid, 5 mg/d, and vitamin B12, 0.4 mg/d
Number of subjects: 29
Study 9412311 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6, 50 mg/d, folic acid, 5 mg/d, and vitamin B12, 0.4 mg/d
Number of subjects: 29
Study 9412311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 8174540 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 microgram kg‐1
Number of subjects: 20
Study 8174540 — intervention group
Group type: COMPARATOR
Intervention: No fentanyl (Control)
Number of subjects: 20
Study 3146370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue plasminogen activator (100 mg over three hours)
Number of subjects: 721
Study 3146370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 721
Study 30221006 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release metformin 250 mg
Number of subjects: 18
Study 30221006 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release metformin 500 mg
Number of subjects: 18
Study 30221006 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release metformin 1000 mg
Number of subjects: 18
Study 30221006 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study 28393817 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% triphala
Number of subjects: 60
Study 28393817 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine
Number of subjects: 60
Study 28393817 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 26084514 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (Gardasil)
Number of subjects: 1598
Study 23932956 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy by mothers
Number of subjects: 66
Study 21812879 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy program + standard diabetes education program
Number of subjects: 145
Study 21812879 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard diabetes education program only)
Number of subjects: 145
Study 19564902 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralidoxime (2 g loading dose over 20 min, followed by 0.5 g/h for up to 7 days)
Number of subjects: 235
Study 19564902 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 235
Study 19564902 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralidoxime
Number of subjects: 235
Study 16724996 — intervention group
Group type: COMPARATOR
Intervention: Gabexate mesilate (900 mg)
Number of subjects: 139
Study 16724996 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ulinastatin (450,000 units)
Number of subjects: 139
Study 16724996 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ulinastatin (150,000 units)
Number of subjects: 139
Study 14655042 — intervention group
Group type: EXPERIMENTAL
Intervention: SCPC abstracts
Number of subjects: 892
Study 14655042 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive studies
Number of subjects: 892
Study 14655042 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment outcomes
Number of subjects: 892
Study 14655042 — intervention group
Group type: EXPERIMENTAL
Intervention: Health services research
Number of subjects: 892
Study 14655042 — intervention group
Group type: EXPERIMENTAL
Intervention: Literature reviews
Number of subjects: 892
Study 14655042 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone metastases
Number of subjects: 892
Study 14655042 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary lung tumors
Number of subjects: 892
Study 14655042 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain metastases
Number of subjects: 892
Study 14655042 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated palliative radiotherapy clinics
Number of subjects: 892
Study 11291347 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone tubes used to enclose the injured zone of transsected ulnar and median nerves
Number of subjects: 7
Study 11291347 — intervention group
Group type: COMPARATOR
Intervention: Conventional microsurgical repair of the nerve trunk
Number of subjects: 7
Study 9423911 — intervention group
Group type: EXPERIMENTAL
Intervention: All-suture release (ASR)
Number of subjects: 30
Study 9423911 — intervention group
Group type: COMPARATOR
Intervention: Selective suture release (SSR)
Number of subjects: 30
Study 8487666 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (200 mg/wk intramuscularly)
Number of subjects: 14
Study 8487666 — intervention group
Group type: EXPERIMENTAL
Intervention: Testolactone (250 mg four times per day)
Number of subjects: 14
Study 8487666 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined testosterone and testolactone
Number of subjects: 14
Study 8487666 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 14
Study 3232537 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (2 different doses)
Number of subjects: 57
Study 3232537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 3232537 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (test drug and placebo)
Number of subjects: 57
Study 31928490 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily dispersion of EGCG complexed with NOPE
Number of subjects: 138
Study 31928490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 29298660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic radiotherapy to the resection cavity (total dose of 46 Gy in 2 Gy per fraction or 36 Gy in 3 Gy per fraction)
Number of subjects: 0
Study 29298660 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 0
Study 27521557 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 772
Study 27521557 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 772
Study 24569129 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 (440/200 μg)
Number of subjects: 50
Study 23699763 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (0.5 μg/kg/min for 4 hours)
Number of subjects: 20
Study 23699763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20482496 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 500
Study 20482496 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMBG)
Number of subjects: 500
Study 18427133 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 to 10 mg) for 8 weeks
Number of subjects: 11
Study 18427133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 21485725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 64
Study 21485725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 16048650 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim/sulfamethoxazole 1 double-strength tablet twice daily for 3 days
Number of subjects: 157
Study 16048650 — intervention group
Group type: EXPERIMENTAL
Intervention: ciprofloxacin 250 mg twice daily for 3 days
Number of subjects: 157
Study 16048650 — intervention group
Group type: EXPERIMENTAL
Intervention: nitrofurantoin 100 mg twice daily for 7 days
Number of subjects: 157
Study 12373371 — intervention group
Group type: EXPERIMENTAL
Intervention: Light touch to the head or neck
Number of subjects: 0
Study 12373371 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger fixed in a clip
Number of subjects: 0
Study 12373371 — intervention group
Group type: COMPARATOR
Intervention: Free light touch to a pad
Number of subjects: 0